|Bid||44.83 x 3200|
|Ask||45.26 x 900|
|Day's Range||44.76 - 46.45|
|52 Week Range||37.01 - 59.59|
|Beta (3Y Monthly)||0.85|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 28, 2019 - Nov 1, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||60.92|
In 2016 Habib Dable was appointed CEO of Acceleron Pharma Inc. (NASDAQ:XLRN). This report will, first, examine the CEO...
Acceleron (XLRN) delivered earnings and revenue surprises of -41.67% and 1.95%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- BLA and MAA filings of luspatercept for beta-thalassemia- and myelodysplastic syndromes-associated anemia accepted by U.S. Food and Drug Administration and European Medicines Age
Celgene (CELG) beats on earnings and sales in second-quarter 2019. The company raises full-year revenue guidance on solid Pomalyst and Abraxane performances.
Acceleron Pharma Inc. (XLRN) today announced it will host a webcast and conference call on Monday, August 5, 2019 at 5:00 p.m. EDT to discuss its second quarter 2019 operating and financial results. The webcast will be accessible under "Events & Presentations" in the Investors/Media page of the company's website at www.acceleronpharma.com. The archived webcast will be available for replay on the Acceleron website approximately two hours after the event.
Acceleron Pharma Inc. (XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today it has completed target enrollment of patients with pulmonary arterial hypertension (PAH) in the PULSAR Phase 2 trial of sotatercept. The Company now expects to report top-line results during the first quarter of 2020. “We’re thrilled with PULSAR’s rapid enrollment over the past 12 months, which underscores the urgency for new therapeutic options for patients with PAH,” said Janethe de Oliveira Pena, MD, PhD, Vice President, Pulmonary Medical Research at Acceleron.
Acceleron Pharma Inc. (XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today that company co-founder Tom Maniatis, PhD, is retiring from his position on its Board of Directors and will continue to serve the organization in an advisory capacity as Director Emeritus. “Tom co-founded Acceleron in 2003 and has been on the Board from day one,” said Francois Nader, MD, Chairman of Acceleron Pharma. “During this period, Tom’s unparalleled scientific instincts and acumen were instrumental in turning a belief in the promise of a fundamental biological pathway into a company on the verge of delivering its first product to patients.
Shares of biotech company Celgene rose Tuesday after the FDA accepted its application for an Acceleron Pharma-partnered anemia treatment in beta thalassemia and some blood cancers.
Celgene Corporation (CELG) and Acceleron Pharma Inc. (XLRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted Celgene’s Biologics License Application (BLA) for luspatercept, an investigational erythroid maturation agent, for the treatment of adult patients with very low to intermediate-risk myelodysplastic syndromes (MDS)-associated anemia who have ring sideroblasts and require red blood cell (RBC) transfusions, and for the treatment of adult patients with beta-thalassemia-associated anemia who require RBC transfusions. The FDA has granted Priority Review to this BLA for the evaluation of the beta-thalassemia indication and set a Prescription Drug User Fee Act (PDUFA), or target action, date of December 4, 2019.
Geron (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late stage studies for patients with MDS and myelofibrosis. The candidate is progressing well in clinical studies.
Acceleron Pharma Inc. (XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that members of the management team will present at the UBS Global Healthcare Conference on Monday, May 20th, 2019 at 11:00 a.m. EDT in New York, NY. A live audio webcast will be available on the Investors/Media page of the Company's website at www.acceleronpharma.com. Acceleron is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases.
Acceleron (XLRN) delivered earnings and revenue surprises of -10.45% and -24.76%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 74 cents. The results fell short of Wall Street expectations. The average estimate of six analysts surveyed by Zacks ...